Noradrenaline metabolism in venous wall

Noradrenaline metabolism in the venous wall refers to the enzymatic degradation of the neurotransmitter noradrenaline (norepinephrine) within venous tissues, a process primarily mediated by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) [1, 2]. This metabolic pathway is a critical regulator of venous tone, as noradrenaline is the principal mediator of venous smooth muscle contraction; its degradation terminates the vasoconstrictive signal [3]. In conditions such as chronic venous disease (CVD) and varicose veins, impaired venous tone leads to blood pooling and venous hypertension [4]. Venoactive drugs, most notably the micronized purified flavonoid fraction (MPFF) containing diosmin and hesperidin, target this process by inhibiting COMT and potentially MAO [2, 5]. This inhibition prolongs the presence of noradrenaline at the neuro-effector junction, thereby increasing venous wall tension, reducing venous capacitance, and improving blood return to the heart [1, 5]. Additionally, these drugs may reduce oxidative stress associated with MAO activity in diseased veins [2]. Targeting noradrenaline metabolism is thus a key pharmacological strategy for managing the symptoms of peripheral venous disorders [4, 5]. Sources: [1] NIH (https://pubmed.ncbi.nlm.nih.gov/14728206/), [2] ResearchGate (https://www.researchgate.net/publication/373984345), [3] StatPearls (https://www.ncbi.nlm.nih.gov/books/NBK537259/), [4] MDPI (https://www.mdpi.com/1422-0067/23/9/5197), [5] Vasculera (https://vasculera.com/).

Other names

Norepinephrine metabolism in venous wallVenous noradrenaline degradationCatecholamine metabolism in the venous wall

Inhibition of catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) to prolong noradrenaline-induced venous smooth muscle contraction.